(MedPage Today) -- SAN ANTONIO -- In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus standard endocrine…
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to…
Pfizer reports Phase 3 results showing Tukysa with trastuzumab and pertuzumab prolonged progression-free survival by 8.6 months in HER2+ metastatic breast cancer.
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off…
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor …
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to…
(MedPage Today) -- At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA) vaccine designed to help prevent triple-negative breast cancer (TNBC), particularly among…
(MedPage Today) -- At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular profiling to improve…
Metastasis occurs when cancer cells break away from the original tumor and travel through the bloodstream to form new tumors in other parts of the body. It is the leading cause of cancer-related death. Brain metastasis is particularly…
(MedPage Today) -- At the San Antonio Breast Cancer Symposium (SABCS), a large retrospective analysis of U.S. electronic health records compared outcomes for patients with HER2-positive metastatic breast cancer who received first-line…
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine…
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the…
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off…
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1–3) hormone receptor …
In Estonia, breast cancer screening is offered from the age of 50, yet one-fifth of first diagnoses occur in younger women. A new clinical study has therefore been conducted to test better ways to detect the disease early.